世界最先端の研究で医学の発展に寄与

2018年

  1. Yasuma-Mitobe, K., and Matsuoka, M. The Roles of Coinhibitory Receptors in Pathogenesis of Human Retroviral Infections. Front Immunol. 9, 2755,2018.
  2. Naito, T., Yasunaga, JI., Mitobe, Y., Shirai, K., Sejima, H., Ushirogawa, H., Tanaka, Y., Nakamura, T., Hanada, K., Fujii, M., Matsuoka, M., and Saito, M. Distinct gene expression signatures induced by viral transactivators of different HTLV-1 subgroups that confer a different risk of HAM/TSP. Retrovirology. 15, 72, 2018.
  3. Song, Z., Wu, W., Chen, M., Cheng, W., Yu, J., Fang, J., Xu, L., Yasunaga, JI., Matsuoka, M., and Zhao, T. Long noncoding RNA ANRIL supports proliferation of adult T-cell leukemia cells through cooperation with EZH2. J Virol. 92, pii: e00909-18. doi: 10.1128/JVI.00909-18,2018.
  4. Inoue, Y., Endo, S., Matsuno, N., Kikukawa, Y., Shichijo, T., Koga, K., Takai, A., Iwanaga, K., Nishimura, N., Fuji, S., Fukuda, T., Nosaka, K., and Matsuoka, M. Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell. Bone Marrow Transplant. Epub 2018 Aug 16. doi: 10.1038/s41409-018-0291-5,2018.
  5. Sato, T., Coler-Reilly, ALG., Yagishita, N., Araya, N., Inoue, E., Furuta, R., Watanabe, T., Uchimaru, K., Matsuoka, M., Matsumoto, N., Hasegawa, Y., and Yamano, Y. Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy. New Engl J Med. 378, 529-538,
  6. Mahgoub, M., Yasunaga, JI., Iwami, S., Nakaoka, S., Koizumi, Y., Shimura, K., and Matsuoka, M. Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells. Proc Natl Acad Sci USA. 378, 529-538,
  7. Tanaka, A., and Matsuoka, M. HTLV-1 Alters T Cells for viral persistence and transmission. Front Microbiol. 9, 461,2018.
  8. Yasunaga, JI., and Matsuoka, M. Oncogenic spiral by infectious pathogens: The cooperation of multiple factors in cancer development. Cancer Sci. 109, 24-32,
  9. Fuji S, Kurosawa S, Inamoto Y, Murata T, Utsunomiya A, Uchimaru K, Yamasaki S, Inoue Y, Moriuchi Y, Choi I, Ogata M, Hidaka M, Yamaguchi T, Fukuda T. Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis. Bone Marrow Transplant. 53(7):905-8, 2018.
  10. Fuji S, Utsunomiya A, Inoue Y, Miyagi T, Owatari S, Sawayama Y, Moriuchi Y, Choi I, Shindo T, Yoshida SI, Yamasaki S, Yamaguchi T, Fukuda T. Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation. Haematologica. 103(5):e211-e4, 2018.
  11. Ishida T, Jo T, Takemoto S, Suzushima H, Suehiro Y, Choi I, Yoshimitsu M, Saburi Y, Nosaka K, Utsunomiya A, Kobayashi Y, Yamamoto K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Imada K, Kato K, Moriuchi Y, Yoshimura K, Takahashi T, Tobinai K, Ueda R. Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation. Br J Haematol. 184(3):479-83, 2019.
  12. Inoue Y, Fuji S, Tanosaki R, Inamoto Y, Tanaka T, Ito A, Okinaka K, Kurosawa S, Kim SW, Nakagama H, Fukuda T. Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma. Bone Marrow Transplant. 53(9):1105-15, 2018.
  13. Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Choi I, Otsuka E, Henzan H, Kato K, Nakachi S, Yamamoto H, Fukuda T. Impact of pretransplant central nervous system invasion in patients with aggressive adult T-cell leukemia lymphoma. Bone Marrow Transplant. Epub 2018/06/15. doi: 10.1038/s41409-018-0248-8,2018.
  14. Yuki A, Shinkuma S, Hayashi R, Fujikawa H, Kato T, Homma E, Hamade Y, Onodera O, Matsuoka M, Shimizu H, Iwata H, Abe R. CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases. Journal of the American Academy of Dermatology. 79(6):1039-46, 2018.
  15. Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Sawada K, Takayama N, Hanamura I, Nagai H, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K, Japan Clinical Oncology Group- Lymphoma Study G. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. Cancer science. 109(9):2830-40, 2018.
  16. Inoue Y, Endo S, Matsuno N, Kikukawa Y, Shichijo T, Koga K, Takaki A, Iwanaga K, Nishimura N, Fuji S, Fukuda T, Nosaka K, Matsuoka M. Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 54(2):338-42, 2019.
  17. Kuramitsu M, Okuma K, Nakashima M, Sato T, Sasaki D, Hasegawa H, Umeki K, Kubota R, Sasada K, Sobata R, Matsumoto C, Kaneko N, Tezuka K, Matsuoka S, Utsunomiya A, Koh KR, Ogata M, Ishitsuka K, Taki M, Nosaka K, Uchimaru K, Iwanaga M, Sagara Y, Yamano Y, Okayama A, Miura K, Satake M, Saito S, Watanabe T, Hamaguchi I. Development of reference material with assigned value for human T-cell leukemia virus type 1 quantitative PCR in Japan. Microbiology and immunology. 62(10):673-6, 2018.
  18. Hashi K, Imai C, Yahara K, Tahmina K, Hayashi T, Azuma T, Miyabe-Nishiwaki T, Sato H, Matsuoka M, Niimi S, Okamoto M, Hatakeyama M. Evaluating the origin and virulence of a Helicobacter pylori cagA-positive strain isolated from a non-human primate. Sci Rep. 8(1):15981, 2018.
  19. Naito T, Yasunaga JI, Mitobe Y, Shirai K, Sejima H, Ushirogawa H, Tanaka Y, Nakamura T, Hanada K, Fujii M, Matsuoka M, Saito M. Distinct gene expression signatures induced by viral transactivators of different HTLV-1 subgroups that confer a different risk of HAM/TSP. Retrovirology. 15(1):72, 2018.
  20. Yasuma-Mitobe K, Matsuoka M. The Roles of Coinhibitory Receptors in Pathogenesis of Human Retroviral Infections. Frontiers in immunology. 9:2755, 2018.
  21. Komohara Y, Noyori O, Saito Y, Takeya H, Baghdadi M, Kitagawa F, Hama N, Ishikawa K, Okuno Y, Nosaka K, Seino KI, Matsuoka M, Suzu S. Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma. Journal of clinical and experimental hematopathology : JCEH. 58(4):152-60, 2018.
  22. Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, Horwitz S, Fields P, Tanase A, Bumbea H, Cwynarski K, Taylor G, Waldmann TA, Bittencourt A, Marcais A, Suarez F, Sibon D, Phillips A, Lunning M, Farid R, Imaizumi Y, Choi I, Ishida T, Ishitsuka K, Fukushima T, Uchimaru K, Takaori-Kondo A, Tokura Y, Utsunomiya A, Matsuoka M, Tsukasaki K, Watanabe T. Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 37(8):677-87, 2019.
  23. Tagaya Y, Matsuoka M, Gallo R. 40 years of the human T-cell leukemia virus: past, present, and future. F1000Research. 8, 2019.
  24. Kawashima I, Inamoto Y, Maeshima AM, Nomoto J, Tajima K, Honda T, Shichijo T, Kawajiri A, Takemura T, Onishi A, Ito A, Tanaka T, Fuji S, Kurosawa S, Kim SW, Maruyama D, Tobinai K, Kobayashi Y, Fukuda T. Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 24(2):294-300, 2018.
  25. Shichijo T, Fuji S, Tajima K, Kubo H, Nozaki K, Honda T, Yamaguchi J, Kawashima I, Kawajiri A, Takemura T, Onishi A, Ito A, Tanaka T, Inamoto Y, Kurosawa S, Kim SW, Fukuda T. Beneficial impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation: focusing on difference between stem cell sources. Bone Marrow Transplant. 53(5):634-9, 2018.
  26. Ito R, Inamoto Y, Inoue Y, Ito A, Tanaka T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Yamashita T, Fukuda T. Characterization of Late Acute and Chronic Graft-Versus-Host Disease according to the 2014 National Institutes of Health Consensus Criteria in Japanese Patients. Biol Blood Marrow Transplant. 25(2):293-300, 2019.
  27. Shichijo T, Fuji S. Hematopoietic stem cell transplantation for T-cell lymphoma. Adv Cell Gene Ther. 1:e6, 2018.
  28. Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto KJ, Fujita H, Fujioka I, Kimura Y, Aisa Y,   IwanagaE, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T: Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors:  Med Oncol . 35:99,  2018
  29. Hirotomo Nakata, Kenji Maeda, Debananda Das, Simon B. Chang, Kouki Matsuda, Kalapala Venkateswara Rao, Shigeyoshi Harada, Kazuhisa Yoshimura, Arun K. Ghosh, Hiroaki Mitsuya. Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s. Scientific Reports. 9(1):4828, 2019.
  30. Hiroki Kumamoto, Shuhei Imoto, Masayuki Amano, Nobuyo Kuwata-Higashi, Masanori Baba, Hiroaki Mitsuya, Yuki Odanaka, Satoko Shimbara Matsubayashi, Hiromichi Tanaka, Kazuhiro Haraguchi. Synthesis, Anti-HBV, and Anti-HIV Activities of 3’-Halogenated Bis(hydroxymethyl)-cyclopentenyladenines. ACS Medicinal Chemistry Letters. 9(12):1211-1216, 2018.
  31. Arun K. Ghosh, Prasanth R. Nyalapatla, Satish Kovela, Kalapala Venkateswara Rao, Margherita Brindisi, Heather L. Osswald, Masayuki Amano, Manabu Aoki, Johnson Agniswamy, Yuan-Fang Wang, Irene T. Weber, Hiroaki Mitsuya. Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis. Journal of Medicinal Chemistry. 24;61(10):4561-4577, 2018.
  32. Satoru Kohgo, Shuhei Imoto, Ryoh Tokuda, Yuki Takamatsu, Nobuyo Higashi-Kuwata, Manabu Aoki, Masayuki Amano, Hisao Kansui, Kengo Onitsuka, Kenji Maeda, Hiroaki Mitsuya. Synthesis of 4’‐Substituted Purine 2’‐Deoxynucleosides and Their Activity against Human Immunodeficiency Virus Type 1 and Hepatitis B Virus. ChemistrySelect. 3(11): 3313-3317, 2018.
  33. Yamamura A, Kikukawa Y, Tokunaga K, Miyagawa E, Endo S, Miyake H, Hata H, Mitsuya H, Yoshida K, Matsuoka M: Pancytopenia and Myelodysplastic Changes in Aceruloplasminemia: A Case with a Novel Pathogenic Variant in the Ceruloplasmin Gene.: Internal Med.;57(13):1905-1910, 2018
  34. Shimazaki C, Hata H, Iida S, Ueda M, Katoh N, Sekishima Y, Ikeda S, Yazaki M, Fukushima W, Ando Y: Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan: Intern Med. 15;57(2):181-187, 2018.
  35. Fujii E, Inada Y, Kakoki M, Nishimura N, Endo S, Fujiwara S, Wada N, Kawano Y, Okuno Y, Sugimoto T, Hata H: Bufalin induces DNA damage response under hypoxic condition to myeloma cells: Oncology Letters. 15(5):6443-6449, 2018.
  36. Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K: Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma: Hematol Oncol. 36(5):792-800, 2018.
  37. Oda S, Nakaura T, Utsunomiya D, Hirakawa K, Takashio S, Izumiya Y, Tsujita K, Hata H, Ando Y, Yamashita Y: Late iodine enhancement and myocardial extracellular volume quantification in cardiac amyloidosis by using dual-energy cardiac computed tomography performed on a dual-layer spectral detector scanner: Amyloid. 25(2):137-138, 2018.
  38. Endo S, Nishimura N, Kawano Y, Ueno N, Ueno S, Tatetsu H, Komohara Y, Takeya M, Hata H, Mitsuya H, Matsuoka M, Okuno Y: MUC1/KL-6 expression confers an aggressive phenotype upon myeloma cells: Biochemical and Biophysical Research Communications. 507(1-4):246-252, 2018.
  39. Oda S, Nakaura T, Utsunomiya D, Nakaura T, Takashio S, Izumiya Y, Tsujita K, Ueda M,Yamashita T, Ando Y, Kawano Y, Okuno Y, Hata H, Yamashita Y: Role of Noninvasive Diagnostic Imaging in Cardiac Amyloidosis: A Review Cardiovascular Imaging Asia.2(2) 97-106, 2018.
  40. Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, Manier S, Mishima Y, Murakami N, Bustoros M, Pistofidis RS, Reidy M, Shen YJ, Rahmat M, Lukyanchykov P, Karreci ES, Tsukamoto S, Shi J, Takagi S, Huynh D, Sacco A, Tai YT, Chesi M, Bergsagel PL, Roccaro AM, Azzi J, Ghobrial IM: Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression: The Journal of Clinical Investigation. 128(6):2487-2499, 2018.
  41. Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, Liu CJ, Mishima Y, Kokubun K, Manier S, Salem KZ, Huynh D, Sacco A, Forward J, Roccaro AM, Battinelli EM, Ghobrial IM: Platelets enhance Multiple Myeloma progression via IL-1β upregulation: Clinical Cancer Research. 24(10):2430-9, 2018.
  42. Tsukamoto S, Løvendorf MB, Park J, Salem KZ, Reagan MR, Manier S, Zavidij O, Rahmat M, Huynh D, Takagi S, Kawano Y, Kokubun K, Thrue CA, Nagano K, Petri A, Roccaro AM, Capelletti M, Baron R, Kauppinen S, Ghobrial IM: Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche: Leukemia. 32(8):1739-50, 2018.
  43. Oda S, Kawano Y, Okuno Y, Utsunomiya D, Nakaura T, Tsujita K, Yamashita Y: Base-to-apex gradient pattern of cardiac impairment identified on myocardial T1 mapping in cardiac amyloidosis: Radiology Case Reports. 14(1): 72-74, 2018.
  44. Saburi M, Ogata M, Itani K, Kohno K, Soga Y, Kondo Y, Kawano Y, Nakayama T: A rare concurrence of indolent B-cell lymphoma and plasmablastic transformation of myeloma: Journal of Clinical and Experimental Hematopathology. 58(4):175-179, 2018.
  45. Oda S, Utsunomiya D, Nakaura T, Takashio S, Izumiya Y, Tsujita K, Ueda M, Yamashita T, Ando Y, Kawano Y, Okuno Y, Hata H, Yamashita Y: Role of Noninvasive Diagnostic Imaging in Cardiac Amyloidosis: A Review: Cardiovascular Imaging Asia. 2(2):97-106, 2018.
  46. Tokunaga K, Yamamura A, Ueno S, Kikukawa Y, Yamaguchi S, Hidaka M, Matsuno N, Kawaguchi T, Matsuoka M, Okuno Y. Isolated Pancreatic myeloid sarcoma associated with t(8;21)/RUNX1-RUNX1T1 rearrangement. Intern Med 57(4): 563-568, 2018.
  47. Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, Takaku T, Iriyama N, Sato E, Fujita H, Hatta Y, Komatsu N, Asou N, Kizaki M, Kawaguchi T. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol 35(3):38, 2018.
  48. Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score. Leuk Lymphoma 59(5): 1105-1112, 2018.
  49. Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto K. J, Fujita H, Fujioka I, Kimura Y, Aisa Y, Iwanaga E, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Med Oncol 35(7): 99, 2018.
  50. Ishikawa J, Matsumura I, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Matsuoka KI, Shibayama H, Hino M, Hirase C, Kamimura T, Shimose T, Akashi K, Kanakura Y. Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial). Int J Hematol 107(5): 535-540, 2018.
  51. Ueda Y, Obara N, Yonemura Y, Noji H, Masuko M, Seki Y, Wada K, Matsuda T, Akiyama H, Ikezoe T, Chiba S, Kanda Y, KawaguchiT, Shichishima T, Nakakuma H, Okamoto S, Nishimura J. I, Kanakura Y, Ninomiya H. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol 107(6): 656-665, 2018.
  52. Kawaguchi T. Management of paroxysmal nocturnal hemoglobinuria: an update. (Review) Rinsho Ketsueki 59(6): 703-710, 2018.
  53. Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol 97(11):2081-2088,
  54. Hosokawa K, Sugimori C, Ishiyama K, Takamatsu H, Noji H, Shichishima T, Obara N, Chiba S, Ninomiya H, Shirasugi Y, Nakamura Y, Ando K, Ueda Y, Yonemura Y, Kawaguchi T, Nishimura J I, Kanakura Y, Nakao S. Establishment of a flow cytometry assay for detecting paroxysmal nocturnal hemoglobinuria-type cells specific to patients with bone marrow failure. Ann Hematol 97(12):2289-2297, 2018.
  55. Iriyama N, Sugimoto K. J, Sato E, Takaku T, Tokuhira M, Nakazato T, Ishikawa M, Fujita H, Fujioka I, Kimura Y, Asou N, Kizaki M, Komatsu N, Hatta Y, Kawaguchi, T. Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis. Med Oncol 35(11): 142, 2018.
  56. Maeda M, Muraki Y, Kosaka T, Yamada T, Aoki Y, Kaku M, Kawaguchi T, Seki M, Tanabe Y, Fujita N, Morita K, Yanagihara K, Yoshida K, Niki Y. The first nationwide survey of antimicrobial stewardship programs conducted by the Japanese Society of Chemotherapy. J Infect Chemother 25(2):83-88, 2019.
  57. Ueda Y, Obara N, Yonemura Y, Noji H, Masuko M, Siki Y, Wada K, Matsuda T, Akiyama H, Ikezoe T, Chiba S, Kanda Y, Kawaguchi T, Shichishima T, Nakakuma H, Okamoto S, Nishimura J, Kanakura Y, Ninomiya H Effects of Eculizumab treatment on Quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan Int J Hematol 107: 656-665 2018.

Hosokawa K, Sugimori C, Ishiyama K, Takamatsu H, Noji H, Shichishima T, Obara N, Chiba S, Ninomiya H, Shirasugi Y, Nakamura Y, Ando K, Ueda Y, Yonemura Y, Kawaguchi T, Nishimura JI, Kanakura Y, Nakao S Establishment of a flow cytometry assay for detecting paroxysmal nocturnal hemoglobinuria-type cells specific to patients with bone marrow failure. Ann Hematol 97: 2289-2297 2018.

お気軽にお問い合わせください TEL 096-373-5156 受付時間 9:00 - 18:00 [ 土・日・祝日除く ]

  • Facebook
  • Hatena
  • twitter
  • Google+
PAGETOP
Powered by WordPress & BizVektor Theme by Vektor,Inc. technology.